Product Comparison


 
Sanofi Pasteur 49281072010
Sanofi Pasteur 49281012065
McKesson # 1154846 1154838
Description Flublok® Quadrivalent 2020 - 2021 Flu Vaccine 180 mcg / 0.5 mL Indicated For People 18 Years and Above Prefilled Syringe 0.5 mL Fluzone® High-Dose 2020 - 2021 Flu Vaccine 180 mcg / 0.7 mL Indicated For People 65 Years of Age and Above Prefilled Syringe 0.7 mL
Manufacturer # 4928107201049281012065
Brand Flublok® Quadrivalent 2020 - 2021Fluzone® High-Dose 2020 - 2021
Manufacturer Sanofi PasteurSanofi Pasteur
Invoice FLUBLOK 2020 QUAD, SYR 0.5ML (10DOSE/BX)FLUZONE 2020, HIGH DOSE QUAD SYR 0.7ML (10DOSE/BX)
    Log In to Order   Log In to Order

Comparison

NDC Number 49281-0720-1049281-0120-65
Strength 180 mcg / 0.5 mL180 mcg / 0.7 mL
User Indicated For People 18 Years and AboveIndicated For People 65 Years of Age and Above
Volume 0.5 mL0.7 mL
Application Flu VaccineFlu Vaccine
Container Type Prefilled SyringePrefilled Syringe
Country of Origin United StatesUnited States
Dosage Form InjectionInjection
Product Dating McKesson Acceptable Dating: we will ship >= 180 daysMcKesson Acceptable Dating: we will ship >= 180 days
Storage Requirements Requires RefrigerationRequires Refrigeration
Type IntramuscularIntramuscular
UNSPSC Code 5120160851201608
Features and Benefits
  • Flublok Quadrivalent is a vaccine indicated for active immunization against disease caused by influenza virus subtypes A and type B contained in the vaccine
  • Flublok Quadrivalent is approved for use in persons 18 years of age and older
  • Flublok contains no egg proteins, antibiotics, or preservatives
  • Flublok Quadrivalent is standardized according to United States Public Health Service (USPHS) requirements. For the 2020 - 2021 influenza season it is formulated to contain 180 mcg HA per 0.5 mL dose, with 45 mcg HA of each of the following 4 influenza virus strains: A/Brisbane/02/2018 (H1N1), A/Kansas/14/2017 (H3N2), B/Maryland/15/2016 (a B/Colorado/6/2017-like virus) and B/Phuket/3073/2013.
  • Fluzone High-Dose is a vaccine indicated for active immunization for the prevention of influenza disease caused by influenza A subtype viruses and type B virus contained in the vaccine
  • Fluzone High-Dose is indicated for active immunization in persons 65 years of age and older
  • Fluzone High-Dose is standardized according to United States Public Health Service requirements and is formulated to contain HA of each of the following three influenza strains recommended for the 2020 - 2021 influenza season: A/Brisbane/02/2018 IVR-190 (H1N1), A/Kansas/14/2017 X-327 (H3N2), and B/Maryland/15/2016 BX-69A (a B/Colorado/6/2017-like virus, B Victoria lineage).